Menu
Recruiting NCT07638462

RIsE Stroke Mobility Study

No phase Interventional Acute Ischemic Stroke

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: activPAL device.
Who it may be relevant to
Registry conditions: Acute Ischemic Stroke. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

RIsEStroke (Recovery Insights Into Early Mobility Post Stroke)

Overview

This study is designed to better understand how patients with severe stroke move during their hospital stay. It will track their activity using a small wearable device (activPAL) along with standard mobility information already collected in clinical care. The goal is to learn what typical movement patterns look like early after a stroke and how well patients meet mobility goals while in the hospital. What is learned from this study may allow determination of how treatment for stroke patients may be improved to improve patient long-term mobility.

Detailed description

Acute Ischemic Stroke (AIS) is a leading cause of disability and death in the United States. However rehabilitation after stroke has shown to reduce the risk of medical and neurological complications and improved brain recovery. There has been extensive research on early mobilization and advanced therapy after AIS in low to moderate stroke severity patients. There has been little research in the mobility of severe AIS patients.

Research studies have utilized several different devices to track movement of subjects. The activPAL device has been used extensively in research studies in a variety of diseases and age groups. The activPAL4pro provides data on posture, limb movement, sleep, sitting and ambulatory movement. For this reason, the activPAL4pro device will be utilized to provide extensive data on our AIS patients.

Interventions

  • Device activPAL device
    The activPAL measures physical activities. When a Participant moves, it moves generating totals for the time spent lying, sitting, standing and stepping, every second of the day.

Primary outcome measures

  • Achievement of the Johns Hopkins Highest Level of Mobility (JH-HLM) goal based on the Activity Measure for Post-Acute Care (AM-PAC) score [Time frame: Daily through Day 14]
Secondary outcome measures (1)
  • Frequency of daily achievement of the JH-HLM goal [Time frame: Daily through Day 14]

Eligibility criteria

Inclusion criteria

  • Adults aged 18 years and older
  • Hospitalized patients with acute ischemic stroke
  • Initial National Institutes of Health Stroke Scale (NIHSS) score of 10 or greater
  • Baseline modified Rankin Scale (mRS) score of 0-2
  • Current modified Rankin Scale (mRS) score of 3-5

Exclusion criteria

  • Current or expected End-of-life discussions
  • Current plans for surgical intervention
  • Patients with pre-mRS of 3-5
  • Patients with orthopedic, musculoskeletal, integumentary injury that would prevent safe weight bearing, mobility or equipment use
  • Uncontrolled cardiorespiratory dysfunction or disease
  • Active/uncontrolled seizures
  • Isolation status that would prevent mobility outside of the room
  • Weight that exceeds the safe limits of mobility equipment

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • Wake Forest University Health Sciences — Winston-Salem

Identifiers

NCT: NCT07638462 · IRB00148157

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗